A promising drug, palbociclib, received accelerated approval as a first line treatment when used with the aromatase inhibitor, letrozole, for postmenopausal women with hormone receptor positive advanced or metastatic breast cancer. We report a case of a patient who presented with febrile neutropenia, grade 3 stomatitis with lip swelling, periorbital edema, and transaminitis while on palbociclib and verapamil. Labs normalized upon discontinuation of verapamil and our patient was able to continue treatment with palbociclib and letrozole. Verapamil’s inhibition of both permeability-glycoprotein (P-gp) and CYP3A4 is suspected to have led to the adverse side effects seen in our patient.
MassarwehSSchiffR. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer2006; 13: S15–S24.
2.
YuYLoiCHoffmanJet al.Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol2016; 57: 173–184.
3.
De GooijerMZhangPThotaNet al.P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs2015; 33: 1012–1019.
4.
BowlesHClarkeK. Palbociclib: a new option for front-line treatment of metastatic, hormone receptor-positive, HER2-negative breast cancer. J Adv Pract Oncol2015; 6: 577–581.
5.
AminM. P-glycoprotein Inhibition for optimal drug delivery. Drug Target Insights2013; 7: 27–34.
6.
MaoQUnadkatJ. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J2014; 17: 65–82.
7.
SharomF. The P-glycoprotein multidrug transporter. Essays Biochem2011; 50: 161–178.
ParrishKPokornyJMittapalliRet al.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther2015; 355: 264–271.
10.
RaubTWishartGKulanthaivelPet al.Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos2015; 43: 1360–1371.
11.
ZhangYGuptaAWangHet al.BCRP Transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res2005; 22: 2023–2034.
12.
MakiNHafkemeyerPDeyS. Allosteric modulation of human p-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem2003; 278: 18132–18139.
13.
KerrDGrahamJCummingsJet al.The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol1986; 18: 239–242.
14.
BergSTolcherAO’ShaughnessyJet al.Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol1995; 13: 2039–2042.
15.
MayerE. Targeting breast cancer with CDK inhibitors. Curr Oncol Rep2015; 17: 443–443.
16.
Gong J, Cho M, Yu KW, et al. A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. Epub ahead of print 7 December 2017. DOI: 10.1007/s10549-017-4606-9.
17.
CristofanilliMTurnerNCBondarenkoIet al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol2016; 17: 425–439.
18.
LasheenSShohdyKKassemLet al.Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther2017; 17: 851–856.
Eli Lilly and Company. Verzenio (package insert), Indianapolis, IN: Eli Lilly and Company, 2017.
21.
KwapiszD. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat2017; 166: 41–54.
22.
RaubTJWishartGNKulanthaivelPet al.Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos2015; 43: 1360–1371.
23.
KimES. Abemaciclib: first global approval. Drugs2017; 77: 2063–2070.
ZhouSXueCYuXet al.Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit2007; 29: 687–710.
26.
HarmszeARobijnsKVan WerkumJet al.The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost2010; 103: 920–925.
27.
MartinPGillenMMillsonDet al.Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from in vitro and phase I clinical studies. Drugs R D2016; 16: 81–92.
